At a broiler integration where drinking-water lines are dosed through a Venturi proportioner, the supplied premix is incorporated into a water-soluble powder that must remain freely dispersible at 25 °C without foaming or forming an oily surface film after 30 minutes of moderate agitation. The formulation addition ratio is 20.0 g of standardised premix per 100.0 g of finished powder, assuming the premix is standardised to ciprofloxacin hydrochloride 50.0% w/w and berberine hydrochloride 25.0% w/w, yielding 10.0 g ciprofloxacin HCl and 5.0 g berberine HCl per 100.0 g. The carrier is spray-dried lactose monohydrate 72.0 g, citric acid anhydrous 6.0 g, and sodium chloride 2.0 g; the buffer system is adjusted to maintain reconstituted solution pH between 3.9 and 4.5 because berberine hydrochloride precipitates as pH rises above 6.0 and fluoroquinolone solubility falls in hard water where calcium and magnesium ions exceed 200 mg/L CaCO₃. Production-scale blending is executed in a 500 kg working-capacity double-cone blender at fill volume 60–65%, rotational speed 8 rpm for 20 minutes, with the citric acid fraction pre-dried to loss-on-drying below 0.5% at 60 °C in a fluid-bed dryer. The blend is passed through a 60-mesh cone mill with a 0.45 mm screen, then packed on a horizontal form-fill-seal line with nitrogen purge into 100 g and 500 g aluminium-laminated foil sachets containing a desiccant pouch. Terminal product type is a veterinary drinking-water soluble powder for on-farm reconstitution at 50 mg ciprofloxacin HCl per litre of drinking water for 3–5 days under veterinary supervision. Compliance is anchored to USP <905> for dosage-unit uniformity where the product is labelled as a unit-dose sachet, USP <61> and USP <62> for microbial limits, and USP <467> for residual ethanol if wet granulation is used. Operational boundary: this powder must not be combined with milk replacer or high-cation premixes due to chelation of the fluoroquinolone by polyvalent cations, and it is not suitable for United States broiler production where extra-label fluoroquinolone administration is prohibited.

Why Are Swine Oral Granules Held at 38–42 °C Bed Temperature During Fluidised-Bed Spray Granulation?

Because the thermal history in this application is governed by the need to avoid over-wetting the lactose-povidone binder while keeping berberine hydrochloride below its moisture-induced agglomeration threshold, the process window is deliberately narrow. A typical batch adds the standardised premix at 40.0 g per 100.0 g of finished granules, yielding 20.0 g ciprofloxacin HCl and 10.0 g berberine HCl per 100.0 g. The carrier is pregelatinised corn starch 35.0 g, microcrystalline cellulose 20.0 g, and povidone K30 5.0 g as a 4% w/w aqueous granulation fluid. Granulation is performed in a fluidised-bed granulator with inlet air temperature 55 ± 5 °C, product bed temperature 38–42 °C, spray nozzle pressure 2.0 bar, and spray rate 120 g/min per 10 kg batch. Product endpoint is defined as loss-on-drying 2.0 ± 0.5% and particle-size D50 450 ± 50 µm measured by sieve analysis. Finished granules are cooled to below 30 °C before discharge, blended with 0.5% sodium stearyl fumarate for 15 minutes, and packed into 5 kg laminated aluminium bags with residual oxygen below 2.0%. Terminal product type is a top-dress medicated granular premix for weaning piglets to be mixed into creep feed at 5 kg per tonne, delivering ciprofloxacin HCl 10 mg/kg body weight and berberine HCl 5 mg/kg body weight daily under prescription. Compliance is framed by current EU GMP for veterinary medicinal products; batch homogeneity is verified by sampling 10 cross-sectional points and assaying by a validated high-performance liquid chromatographic method aligned with USP <905> harmonised acceptance criteria. Operational limitation: the granules must not be stored above 60% relative humidity because berberine hydrochloride absorbs atmospheric moisture and swells at the particle surface, producing segregation and caking in the feed mill hopper. Segregation potential is highest when D50 is below 300 µm or when the carrier is changed to low-bulk-density powdered rice hull without revalidating the top-dress blend.

Companion Animal Tablet Compression Forces and Binder Selection at 75 mg Active Load

For companion animal tablet compression, the brittle fracture characteristics of berberine hydrochloride impose a maximum main compression force near 18 kN; above this value edge capping increases on high-speed rotary presses. Direct compression is rejected because berberine hydrochloride has poor compactibility and ciprofloxacin hydrochloride has poor flow, so wet granulation with povidone K30 at 3.0% w/w is used. The standardised premix is added at 100.0 mg per 300.0 mg tablet core, corresponding to ciprofloxacin hydrochloride 50.0 mg and berberine hydrochloride 25.0 mg, with microcrystalline cellulose PH102 120.0 mg, lactose monohydrate 70.0 mg, crospovidone 6.0 mg, colloidal silicon dioxide 1.5 mg, and magnesium stearate 2.5 mg. Granulation is carried out in a 65 L high-shear mixer-granulator at impeller speed 300 rpm and chopper speed 1500 rpm, wetting with 12% w/w purified water; the wet granules are dried in a fluid-bed dryer at 45 ± 3 °C to loss-on-drying 2.0 ± 0.3%. Tableting is performed on a rotary press with 19.5 × 9.0 mm oval punches at compression force 12–16 kN, target hardness 7–10 kp, and thickness 5.0 ± 0.2 mm. Disintegration is tested per USP <701> in a 37 ± 2 °C water bath; the acceptance limit is ≤15 minutes. Dissolution is performed per USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid with Q = 80% in 45 minutes. Terminal product type is a veterinary prescription tablet packed in amber polyvinyl chloride/polyvinylidene chloride blisters with aluminium foil lidding, supplied as 100 tablets per carton. Compliance includes USP <905> for content uniformity and USP <467> for residual isopropyl alcohol if used as granulation solvent instead of water. Operational limitation: ciprofloxacin hydrochloride can chelate magnesium stearate when the lubricant level exceeds 1.0% and the tablet is stored above 30 °C; therefore the formulation limits magnesium stearate to 0.83% w/w, and stability labelling specifies storage below 25 °C at not more than 60% relative humidity.

When Terminal Sterilisation at 121.1 °C Is Applied to Berberine Hydrochloride Solutions Above pH 5.5

Injectable terminal sterilisation shifts from routine to process-critical when berberine hydrochloride is formulated above pH 5.5 because hydrolytic degradation accelerates during moist-heat exposure, while ciprofloxacin hydrochloride binds polyvalent cations released from Type II glass vials after repeated thermal cycling. For a 100 mL parenteral formula, the standardised premix is added at 2.0 g per 100.0 mL of final solution, based on a premix standardised to ciprofloxacin HCl 50.0% w/w and berberine HCl 25.0% w/w, yielding ciprofloxacin HCl 10.0 mg/mL and berberine HCl 5.0 mg/mL. The remaining formula is water for injection 80.0 mL, disodium edetate 10.0 mg, sodium chloride 0.9 g, lactic acid to pH 4.0 ± 0.2, and nitrogen gas purge throughout compounding. Production is executed in a Class C cleanroom with Class A local protection; the solution is not heated above 80 °C before filtration, because berberine loss increases rapidly with temperature. The solution is pre-filtered through a 0.45 µm polyethersulfone membrane followed by a 0.22 µm sterilising-grade membrane, then filled into 100 mL Type I amber glass vials with a fill volume override of 102.5%. Terminal sterilisation uses an air-overpressure water-spray autoclave with a 12-thermocouple validation array and F₀ ≥15 minutes at 121.1 °C for 15 minutes. After sterilisation the solution is held for 14 days at 25 °C and 60% relative humidity to monitor visible precipitation and pH drift. Terminal product type is a sterile injectable solution for subcutaneous or intravenous administration to cattle and buffalo under veterinary supervision. Compliance is anchored to USP <71> for sterility testing, USP <85> for bacterial endotoxins with a limit of ≤0.6 EU/mg, and USP <788> for particulate matter.

Operational limitation: the formulation must not be adjusted to pH above 5.5 before sterilisation because berberine degradation rises steeply. The addition of calcium gluconate or magnesium salts must be avoided due to fluoroquinolone chelation, and light exposure during storage induces ciprofloxacin photodegradation; amber primary packaging is mandatory.

In ornamental fish breeding facilities that require a water-dispersible antibacterial powder for short-duration immersion, the premix is reformulated into a non-sterile concentrate containing 5.0 g ciprofloxacin HCl and 2.5 g berberine HCl per 100.0 g, achieved by adding 10.0 g of the standardised premix to 90.0 g of acidified sodium sulfate carrier. The immersion-bath ratio is 10 g of concentrate per 100 L of conditioned water, giving 5 mg/L ciprofloxacin HCl and 2.5 mg/L berberine HCl for a 4-hour static bath with continuous aeration. Production is a single-pass ribbon mixer loaded to 50% capacity with a 10-minute blend at 20 rpm, followed by sieving through 80 mesh and packing into 100 g light-resistant polyethylene terephthalate jars. The production area maintains relative humidity below 55% to limit berberine hydrochloride clumping. Terminal product type is a non-sterile ornamental fish bath powder for koi and freshwater ornamental facilities, explicitly not for food-fish species. Compliance is limited to general veterinary Good Manufacturing Practice and environmental discharge control; published data for this specific configuration is limited, so batch users validate tank residues and tank-water antimicrobial activity before release. Operational boundary: do not use with activated-carbon filters running during treatment because carbon removes fluoroquinolone and berberine from the water column, and do not discharge treated water into natural water bodies without prior UV or ozone treatment.

Dosing-pump stability collapses when the concentrate contacts milk-replacer calcium

When reconstituting a ciprofloxacin–berberine concentrate for neonatal calf enteritis, the key variable is not only active solubility but also the exclusion of free calcium from the administration stream, because ciprofloxacin HCl forms a poorly absorbable complex with calcium in milk replacer. A 1 L oral solution concentrate adds the standardised premix at 20.0 g per litre, providing ciprofloxacin HCl 10.0 g/L and berberine HCl 5.0 g/L. The formula is propylene glycol 250.0 mL, citric acid 10.0 g, sodium citrate dihydrate 5.0 g, and purified water q.s. to 1 L. Mixing is performed in a jacketed stainless-steel tank at 35 ± 2 °C for 30 minutes, with nitrogen sparging to reduce dissolved oxygen below 0.5 mg/L. The solution is filtered through a 0.45 µm polypropylene capsule, filled into 1 L amber polyethylene terephthalate bottles, and sealed with induction liners. Terminal product type is a veterinary oral solution concentrate to be administered at 1 mL per 10 kg body weight daily for 3 days, diluted in drinking water rather than milk replacer. Compliance uses USP <1231> for pharmaceutical water quality and USP <61>/USP <62> for non-sterile microbial limits; the production vessel and transfer lines are cleaned with 1.0% sodium hydroxide followed by a citric acid rinse to prevent cross-contamination. Operational limitation: the concentrate must not be added directly to milk replacer due to precipitation of the ciprofloxacin-calcium complex. If oral administration by dosing gun is used, the dosing line must be purged with water after each use because residual product forms a sticky yellow film that hardens in the tube and reduces flow accuracy.